NIH Institute / Center · TR (NCATS)
National Center for Advancing Translational Sciences
106 funded awards, $60.4M total, FY2023-FY2025.
NIH SBIR/STTR funding decisions are made by Institutes and Centers based on portfolio priorities, NOFO scope, and program officer judgment. Historical funding patterns do not guarantee future funding.
Technology areas funded by NCATS
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
Pattern read
NCATS funded 106 records / $60M, with a portfolio focused on translational research tools, small-molecule therapeutic platforms, and cross-cutting modalities (vaccines, cell therapies, gene therapy). Median award is $350K, the lowest among the medium-volume ICs. NCATS Phase II awards have tended to be smaller, often because the work is platform/methods-focused rather than indication-specific. R44/R43 ratio is roughly 1.3:1, more balanced than most ICs. Concentration is 11.3%. NCATS's translational-platform mission shapes the portfolio; indication-specific pitches without a translational-platform angle have not landed.